[Hiring] Commercial Lead @Iovance Biotherapeutics

Role Description

The Commercial Lead, Australia is the senior commercial leader accountable for establishing, commercialising and scaling Iovance’s business in the Australian market. This role owns the Australian commercial strategy and profit-and-loss performance, including revenue, operating expenses, forecasting, resource allocation and achievement of business objectives for AMTAGVI and Proleukin.

• Direct the full sales cycle—from market development, account planning, referral generation and patient identification through treatment-centre activation, completed patient infusions, revenue generation and ongoing account growth.
• Lead the authorisation and commercial activation of AMTAGVI treatment centres and provide operational and quality oversight after authorisation.
• Build executive and clinical relationships across treatment centres and referral networks.
• Ensure medical, nursing, laboratory, pharmacy, quality and administrative stakeholders are prepared to deliver TIL therapy.
• Align internal functions to move eligible patients from identification and referral through tumour procurement, manufacturing coordination, treatment scheduling, completed infusion and revenue recognition.
• Set the country commercialisation strategy, lead launch and market development, and be accountable for commercial performance.
• Represent the Australian business in global planning, investment, forecasting and performance discussions.
• Build the commercial capabilities and organisation required as the market grows.

Qualifications

• A relevant bachelor’s degree or an equivalent combination of education and senior commercial leadership experience; an MBA or other relevant postgraduate qualification is preferred.
• Extensive progressive experience in oncology or biotechnology commercial and customer-facing leadership roles, typically gained through 12 or more years of relevant experience; cell therapy and hospital experience are strongly preferred.
• Demonstrated success leading a pharmaceutical or biotechnology product launch at the country or regional level; solid tumour launch experience is preferred.
• Demonstrated profit-and-loss ownership and delivery against revenue, operating expense, budget and profitability targets.
• Experience leading an end-to-end sales process tied to patient treatment, administration or infusion, including demand generation, patient conversion, completed treatment and revenue recognition.
• Strong forecasting, financial planning, budget management, business analytics and performance-management experience.
• Experience building a market, commercial capability or country organisation with limited existing infrastructure.
• Experience developing and building service lines at public or private teaching hospitals or tertiary hospitals is preferred.
• High clinical aptitude in oncology and immunotherapy, with strong operational and commercial acumen in tertiary hospital and community oncology settings.
• Executive presence and demonstrated ability to influence senior internal and external stakeholders and deliver compelling oral presentations.
• Ability to manage competing priorities, make sound decisions and meet time-sensitive business requirements.
• Ability to lead effectively through influence within a matrix organisation and build organisational capability as the Australian business grows.

Requirements

• Regular use of standard office technology and participation in virtual and in-person meetings.
• The successful candidate must be based in Australia and have ongoing legal working rights in Australia.
• A current driver licence and the ability to undertake regular domestic travel, anticipated to be up to 75%.

Benefits

• Iovance will provide reasonable workplace adjustments during recruitment and employment to enable a suitably qualified person to perform the inherent requirements of the role, unless doing so would cause unjustifiable hardship.

Company Description

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors.

• Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma.
• The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors.
• Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing.